facebook linkedin twitter

FDA Issues Guidance on Development of a Safe and Effective COVID-19 Vaccine

June 30, 2020 by Dan McCue
Dr. Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, testifies before a Senate Health, Education, Labor and Pensions Committee hearing on Capitol Hill in Washington, Tuesday, June 30, 2020. (Kevin Dietsch/Pool via AP)

WASHINGTON – The U.S. Food and Drug Administration released a series of recommendations Tuesday that it say should help facilitate the timely development of a safe and effective COVID-19 vaccine.

The agency said the guidance reflects advice it has been providing over the “past several months” to companies, researchers and others, regarding the clinical development, manufacturing and ultimate approval of a COVID-19 vaccine.

The release of the FDA guidance came hours after White House Health Advisor Dr. Anthoyn Fauci told a senate panel that the U.S. is “not in total control” of the country’s coronavirus outbreak.

“I can’t make an accurate prediction, but it’s going to be very disturbing,” Fauci told senators in a hearing held by the Senate Health, Education, Labor and Pensions Committee. “We are now having 40-plus-thousand new cases a day. I would not be surprised if we go up to 100,000 a day if this does not turn around, and so I am very concerned.”

In rolling out the guidance, FDA Commissioner Dr. Stephen Hahn said the agency recognized the “urgent need” for a COVID-19 vaccine, but added that it would not “cut corners” to get there.

He said the agency is “making clear through this guidance what data should be submitted to meet our regulatory standards.

“This is particularly important, as we know that some people are skeptical of vaccine development efforts,” Hahn said.

“We have not lost sight of our responsibility to the American people to maintain our regulatory independence and ensure our decisions related to all medical products, including COVID-19 vaccines, are based on science and the available data,” he continued. “This is a commitment that the American public can have confidence in and one that I will continue to uphold.”

The FDA also emphasized Tuesday that it has the scientific expertise to evaluate any potential COVID-19 vaccine candidate regardless of the technology used to produce or administer it.

This includes the different technologies such as DNA, RNA, protein and viral vectored vaccines being developed by commercial vaccine manufacturers and other entities.

“In this particular crisis in which there is so much at stake, we need to help expedite vaccine development as much as we can without sacrificing our standards for quality, safety, and efficacy,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

“We firmly believe that transparency regarding the FDA’s current thinking about the scientific data needed to support approval of safe and effective COVID-19 vaccines will help build public confidence in the FDA’s evaluation process, which will be critical in ensuring their use,” he said.

“Right now, neither the FDA nor the scientific community can predict how quickly data will be generated from vaccine clinical trials,” Marks continued. “Once data are generated, the agency is committed to thoroughly and expeditiously evaluating it all. But make no mistake: the FDA will only approve or make available a COVID-19 vaccine if we determine that it meets the high standards that people have come to expect of the agency.”

The guidance, “Development and Licensure of Vaccines to Prevent COVID-19,” provides an overview of key considerations to satisfy requirements for chemistry, manufacturing and control, non-clinical and clinical data through development and licensure, and for post-licensure safety evaluation.

The FDA strongly encourages the inclusion of diverse populations in all phases of clinical development, including populations most affected by COVID-19, specifically racial and ethnic minorities, as well as adequate representation in late phase trials of elderly individuals and those with medical issues.

Sponsors are also encouraged to include studies in their development plans that would provide data to support use during pregnancy, as well as plans for pediatric assessments of safety and effectiveness.

The guidance also discusses the importance of ensuring that the sizes of clinical trials are large enough to demonstrate the safety and effectiveness of a vaccine. It conveys that the FDA would expect that a COVID-19 vaccine would prevent disease or decrease its severity in at least 50% of people who are vaccinated.

Additionally, after approval by the FDA, the safety of all vaccines, including a COVID-19 vaccine, continues to be closely monitored using various existing surveillance systems. The FDA may also require post-marketing studies to further assess known or potential serious risks.

Among those welcoming the release of the guidance Tuesday was House Speaker Nancy Pelosi, who said, “The whole world is praying for a coronavirus vaccine, but it must be effective and safe to be the answer to our prayers.”

She also underscored its importance in ensuring Americans have confidence in any vaccine the agency approves “in light of the immense political pressure on the FDA to deliver a vaccine as soon as possible.”

Toward this end, she reiterated how important it is that vaccines have a trial size of at least 30,000, including diverse populations in all phases of clinical development, especially racial and ethnic minorities.

That it be found to be at least 50% more effective than a placebo.

And that there must be full transparency throughout the vaccine approval process, including public advisory committee review by the FDA before an emergency use authorization for a new vaccine is approved.

The FDA should also track the health of those vaccinated for at least a year after vaccination, to ensure we understand the long-term safety of the vaccine, Pelosi said.

“Anything less than the FDA’s ‘Development and Licensure of Vaccines to Prevent COVID-19’ guidance would jeopardize the confidence the American people have in the vaccine. We are grateful for this guidance, which gives us hope,” she concluded.

In The News

Health

Voting

Health

August 5, 2021
by Alexa Hornbeck
The New Social Determinants Caucus

Two weeks ago, Reps. Cheri Bustos, D-Ill.,Tom Cole, R-Okla., G.K. Butterfield, D-N.C., and Markwayne Mullin, R-Okla., created a new Social... Read More

Two weeks ago, Reps. Cheri Bustos, D-Ill.,Tom Cole, R-Okla., G.K. Butterfield, D-N.C., and Markwayne Mullin, R-Okla., created a new Social Determinants Caucus, which will coordinate federal investments in health and social drivers of health such as food, housing and transportation. “The reason you start a caucus... Read More

August 5, 2021
by Alexa Hornbeck
New Rules Could Take Californiaʼs Pork Supply Offline

The California Farm Confinement Proposition, known as Prop 12, is set to become effective next year and could mean that... Read More

The California Farm Confinement Proposition, known as Prop 12, is set to become effective next year and could mean that pork suppliers lose access to California’s large market. The law will implement space requirements for chickens, calves, and hogs, such as retrofitting buildings, and will also... Read More

Head of UN Health Agency Seeks Vaccine Booster Moratorium

GENEVA (AP) — The head of the World Health Organization called Wednesday for a moratorium on administering booster shots of... Read More

GENEVA (AP) — The head of the World Health Organization called Wednesday for a moratorium on administering booster shots of COVID-19 vaccines as a way to help ensure that doses are available in countries where few people have received their first shots.  WHO Director-General Tedros Adhanom... Read More

August 4, 2021
by Alexa Hornbeck
Genome Sequencing of Newborns Can Save Lives and Lower Medical Costs

Over the last decade evidence has shown that whole genome sequencing saves lives, but a new study from researchers in... Read More

Over the last decade evidence has shown that whole genome sequencing saves lives, but a new study from researchers in California shows how genome sequencing for newborns in intensive care units can also save money. “We now know there are more than 6,000 genetic diseases, but... Read More

August 4, 2021
by Alexa Hornbeck
COVID-19 Pandemic Increases Demand for Cosmetic Procedures

As COVID-19 lockdown orders have lifted and many individuals are returning to social activities, cosmetic surgeons across the country are... Read More

As COVID-19 lockdown orders have lifted and many individuals are returning to social activities, cosmetic surgeons across the country are seeing an increase in the demand for cosmetic procedures. “I’ve never seen a jump this high, most practices do get busier and it’s pretty predictable, but... Read More

Fauci: More 'Pain and Suffering' Ahead as COVID Cases Rise

Dr. Anthony Fauci warned Sunday that more "pain and suffering" is on the horizon as COVID-19 cases climb again and... Read More

Dr. Anthony Fauci warned Sunday that more "pain and suffering" is on the horizon as COVID-19 cases climb again and officials plead with unvaccinated Americans to get their shots. Fauci, the nation's top infectious disease expert, also said he doesn't foresee additional lockdowns in the U.S.... Read More

News From The Well
scroll top